Type 1 dendritic cells are key to initiate and maintain anti-tumoral T-cell responses in diverse tumour tissues. Our lab focuses on tissue-specific properties of cDC1 in lung tumours, focusing on the ...

Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced ...

KRAS driver mutations are found in greater than ... alteration-specific therapeutics to address high-value and validated oncogenic drivers. Our pipeline includes two Phase 1 therapies in ...

This patent aims to develop small-molecule inhibitors targeting mutant KRAS proteins to block oncogenic signaling. The patent describes compounds designed to selectively inhibit KRAS mutations by ...

Every day, billions of cells in your body divide, helping to replace old and injured cells with new ones. And each time this ...

Researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a potential therapeutic target in cancer.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

KRAS is the most frequently mutated oncogene in human cancer and drives the disease in up to 50% of patients with CRC, according to BMS. The KRAS G12C mutation occurs in approximately 3% to 4% of ...

WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.